Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Pimasertib (Primary) ; Voxtalisib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors EMD Serono; Merck KGaA
- 28 Jul 2017 Planned End Date changed from 1 Nov 2017 to 30 Nov 2019.
- 10 Jun 2017 Biomarkers information updated
- 22 Feb 2017 Planned End Date changed from 1 May 2016 to 1 Nov 2017.